A Prospective, Randomized, Placebo-controlled Comparative Study of Amino Acid Supplementation in Lactation Insufficiency

Nagarathnamma R1, Pooja Bhushan2, Trayambak Dutta3, Ezhil Arasan R4

Abstract

Objective: Our study evaluates the clinical efficacy of intravenous (i/v) amino acids in the prevention of lactation insufficiency and improvement of neonatal weight gain.

Design: A prospective, randomized, open-label, placebo-controlled clinical trial is reported.

Population or sample: This study recruited 305 lactating mothers of age-group, 22–35 years.

Methods: Test group, n = 152, received i/v amino acid infusion, 500 mL, as study drug once daily for 4 days, and control group, n = 153, received normal saline as placebo, 500 mL od for 4 days.

Main outcome measures: We studied the efficacy and safety of i/v amino acids in the prevention of lactation insufficiency. We further evaluated the role of maternal amino acid supplementation in ameliorating physiological weight loss and overall neonatal weight gain.

Results: Lactation onset was reported in 86.3% of mothers in the amino acid group at day 0 as compared to 32.23% in the control group (p value < 0.001). Lactation was achieved by all the mothers in the study group by day 1 itself with two doses of i/v amino acids (p value < 0.001). An increase in neonatal weight was observed in the amino acid group, (2.900 ± 0.488, p value = 0.001) compared with the control group at 2 weeks (2.716 ± 0.484, p value = 0.001).

Conclusion: Maternal amino acid supplementation is proven to be both efficacious and safe in augmenting breast milk production, thereby preventing lactation insufficiency. It effectively prevented neonatal physiological weight loss at 2 weeks and promoted substantial weight gain over a period of a month after birth.

Keywords: Amino acids, Lactation insufficiency, Neonatal weight.

Introduction

Lactation insufficiency is a major issue of neonatal health. Poor breast milk production is the most frequent cause of lactation insufficiency. Inadequate milk production accounts for a substantial aggregate of lactation insufficiency cases worldwide. The World Health Organization recommends exclusive breastfeeding for the first 6 months of life starting 1 hour after delivery. Only 42% of newborns are put to the breast within the first hour of birth, globally and only two in five infants less than 6 months of age are exclusively breastfed. Breast milk substitutes increase the risk of mortality and morbidity among infants in developing countries and shorten birth intervals. Mothers delivering by cesarean section (C-section) are less likely to breastfeed or delay breastfeeding initiation. C-section-delivered babies lack skin-to-skin contact immediately after birth with their mothers and the latter is more likely not to have attempted breastfeeding within the first 24 hours after delivery. Breastfeeding is associated with the infant’s health benefits, such as improved intelligence as adults, lower cholesterol levels, stable blood pressure, fewer childhood illnesses, and lower prevalence of obesity. Preterm deliveries contribute to lactation insufficiency. In shortened pregnancies, mammary growth is incomplete and insufficiently primed for adequate lactogenesis. A low placental lactogen level along with poor placental function aggravates lactation insufficiency. Lactation is inhibited by fatigue, anxiety, and the stress of preterm delivery. Preterm mothers are incapable of responding to stimulation of milk synthesis and expression, thereby leading to lactation insufficiency. Lack of breastfeeding in preterm infants is associated with a 2.4-fold risk of necrotizing enterocolitis. Since the case fatality rate for necrotizing enterocolitis is 15%, this difference in absolute risk is clinically significant. Poor maternal nutritional status especially before the onset of labor till the delivery of the newborn augments lactation insufficiency. A constant decrease in the levels of both maternal and fetal essential amino acid concentration is evident at full-term and pre-delivery. Animal studies have shown that amino acids can be considered as

© Jaypee Brothers Medical Publishers. 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
A valid therapeutic option to enhance milk production in lactation insufficiency with minimal side effects. Amino acids activate mammalian target of rapamycin (mTOR) signaling pathway in the mammary epithelial cells, thereby synthesizing milk proteins, i.e., caseins, α-lactalbumin, and β-lactoglobulins. This improves the quality of breast milk. Although animal studies are available, human clinical trials are lacking study efficacy and tolerability of intravenous (i/v) amino acids in the prevention of lactation insufficiency, and hence we did this study.

**Materials and Methods**

**Setting**
Rajarajesswari Medical College (RMC), Bengaluru, India, Department of Obstetrics, has 3,500 births per annum and is a tertiary referral center with level three neonatal intensive care facilities. The RMC Labor Ward is directly supervised by a senior registrar with 10–15 years of specialist training in obstetrics, 24 hours a day. In addition, there is one junior registrar (with 3 years of specialist training) and an intern trainee. Throughout the study period, there were at least 50 hours per week of direct consultant presence. Out of these periods, there was always indirect consultant supervision.

**Participants**
We examined the 305 nursing mothers of age-group 22–35 years.

**Case Identification and Data Validation**
For the 12-month period from October 2, 2018, to September 30, 2019, all pregnant women at term were screened by detailed medical history, vital signs, general, systemic examinations, and laboratory investigations. Mothers who delivered via normal vaginal delivery and C-section were included while pregnancy-induced hypertension, renal failure, gestational diabetes mellitus, and elderly primigravida were excluded from the study. The final dataset was entered into an Excel spreadsheet and migrated into the department of statistical medicine for analysis. RMC ethical committee approved the study. This trial was registered at the Clinical Trials Registry of India (CTRI) vide no.-CTRI/2019/02/017650.

**Demographics and Other Confounders**
The following maternal demographic variables were collected: age at delivery, parity, mode of delivery, lactation onset, and urine output. Neonatal sleep quality, weight changes, and requirement of phototherapy were collected. The test group (n = 152) received i/v amino acid infusion, 500 mL, od for 4 days and the control group (n = 153) received normal saline, i/v, 500 mL, od for 4 days. Both placebo and study drug were administered 1 hour after delivery followed by a single dose every day till day 3 of birth. The study drug comprises isoleucine 5.6 mg, leucine 12.5 mg, lysine hydrochloride 11.0 mg, methionine 3.5 mg, phenylalanine 9.35 mg, threonine 6.5 mg, tryptophan 1.3 mg, valine 4.5 mg, histidine hydrochloride 8.11 mg, arginine hydrochloride 9.55 mg, alanine 6.2 mg, aspartic acid 3.8 mg, cysteine hydrochloride 1.45 mg, glutamic acid 6.5 mg, proline 3.3 mg, serine 2.2 mg, tyrosine 0.35 mg, glycine 10.7 mg, and xylitol 50.0 mg.

**Outcome Variables**
Maternal outcome variables collected were the efficacy of administration of i/v amino acids in reducing the time of onset of lactation. Weight and sleep pattern were the neonatal outcomes measured.

**Statistical Analysis**
Pearson Chi-square test was used to evaluate parity, mode of delivery, lactation onset, urine output, baby sleep pattern, phototherapy requirement, and adverse drug reactions. Test was employed to analyze intergroup comparison of gestational age and neonatal weight gain across and within the groups.

**Results**
This clinical trial included 305 patients with the control group, n = 152, and the study group, n = 153 patients, as per Figure 1. The groups were evaluated with respect to parity, mode of delivery, lactation onset, urine output, sleep of the baby, and requirement of phototherapy. In terms of parity, 41.8% of the control group was primigravida and 45.1% were multigravida. In the study group, 45.1% were primigravida and 54.9% were multigravida. In the study group, 45.1% underwent lower segment cesarean section (LSCS), whereas 54.9% of the mothers delivered by vaginal delivery. In the control group, 41.2% underwent LSCS whereas 58.8% delivered by vaginal delivery (Table 1). At day 0 of birth, lactation onset was observed in 86.3% of the mothers in the amino acid group as compared to only 32.23% in the control group (p < 0.001) as depicted in Figure 2. Lactation was achieved by all the mothers in the study group by day 1 itself with two doses of i/v amino acids (p < 0.001). The control group achieved 100% lactation only by day 3. Physiological weight loss during the early weeks of birth was observed in the control group but not in the study group. Figure 3 demonstrates a statistically significant increase in weight as observed in the amino acid group, (2.900 ± 0.488, p = 0.001) and a month after birth (4.007 ± 0.501, p < 0.001).

![CONSORT diagram](image)

**Table 1: Demographic data**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Amino acids (%)</th>
<th>Control (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode of delivery</td>
<td>C-section</td>
<td>45.1</td>
<td>41.2</td>
</tr>
<tr>
<td>Normal delivery</td>
<td>54.9</td>
<td>58.8</td>
<td></td>
</tr>
<tr>
<td>Primigravida</td>
<td>45.1</td>
<td>41.8</td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td>Multigravida</td>
<td>54.9</td>
<td>58.2</td>
</tr>
</tbody>
</table>
compared with the control group at 2 weeks (2.716 ± 0.484, \( p = 0.001 \)) and after a month after birth (3.692 ± 0.501, \( p < 0.001 \)). Weight gain was significantly higher in the treatment group at 2 weeks, (2.900 ± 0.488, \( p < 0.001 \)) and a month after birth (4.007 ± 0.501, \( p < 0.001 \)). Babies had better sleep in the amino acid group as compared to the control group (\( p < 0.001 \), Table 2).

In the amino acid group, 90.8% of the babies had sound sleep compared to 69.9% in the control group. In terms of phototherapy, 83.7% of babies did not require phototherapy in the amino acid group compared to 68.7% in the control group (\( p = 0.002 \), Table 2).

In the amino acid group, 2 patients reported itching at the site of injection and forearm while no adverse events were reported in the control group. Dropouts were registered due to excessive lactation in 24.8% of the cases in the amino acid group with the first dose compared to 0.7% cases in the control group (\( p < 0.001 \)).

**Discussion**

To our knowledge, this is the first human clinical trial with 305 patients, which evaluates the clinical efficacy of i/v amino acids in the prevention of lactation insufficiency and improvement of neonatal weight gain. Upon administering amino acids, 86.3% of the mothers undergoing C-section achieved lactation on day 0 of birth compared to the control group (\( p < 0.001 \)). The lactation achieved by the study group was absolute by day 1 after delivery (\( p < 0.001 \)). Weight gain achieved in the amino acid group was persistent compared to the control group. Weight gain was observed in the amino acid group (2.900 ± 0.488, \( p = 0.001 \)), and a month after birth (4.007 ± 0.501, \( p < 0.001 \)) as compared with the control group at 2 weeks (2.716 ± 0.484, \( p = 0.001 \)) and a month after birth (3.692 ± 0.501, \( p < 0.001 \)). Weight gain was reported within the amino acid group at 2 weeks (2.900 ± 0.488, \( p < 0.001 \)), and a month after birth (4.007 ± 0.501, \( p < 0.001 \)). Amino acid supplementation prevented the usual reduction in weight at 2 weeks after birth which is an important clinical outcome of our study. In an intergroup analysis, an increase of 200 gm was noted between babies in the amino acid group as compared to the control group at 2 weeks (amino acid group: 2.9007 ± 0.488, control group: 2.7169 ± 0.484, \( p < 0.001 \)). Lactation onset was observed in 86.3% of the mothers in the amino acid group at day 0 as compared to only 32.23% in the control group (\( p < 0.001 \)).

In a randomized control trial in mammals, six lactating cows were randomly assigned to treatment groups with 21 days for each

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Amino acid group (%)</th>
<th>Control group (%)</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phototherapy requirement</td>
<td>16.3</td>
<td>31.4</td>
<td>0.002</td>
</tr>
<tr>
<td>Undisturbed baby sleep</td>
<td>90.8</td>
<td>69.9</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Table 2: Phototherapy requirement and baby sleep

**Fig. 2:** Lactation onset

**Fig. 3:** Weight gain
Amino Acid Supplementation in Lactation Insufficiency

Caseins are responsible for improving milk qualitatively and quantitatively. α-lactalbumins and β-lactoglobulins increase lactose content.

Non-phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) inhibits protein synthesis by combining with the eukaryotic translation initiation factor 4E (eIF4E).

Phosphorylation activates mTORC1 via 4EBP1 at multiple sites and subsequently causes the release of eIF4E from 4EBP1-eIF4E complex.

Once released, eIF4E forms an active translation initiation complex. The translation initiation complex then binds the 40S ribosomal subunit, generating the 43S pre-initiation complex, thereby initiating translation of mRNA into protein.

The mTORC1 receptor is activated by amino acids, particularly arginine, leucine, glycine, tryptophan, and glutamine.

Leucine enhances overall protein synthesis by serving as a precursor for the synthesis of glutamine, aspartate, glutamate, and asparagine.

Mechanism of Amino Acids in Lactation

Amino acids regulate metabolic pathways for whole-body homeostasis. They get catabolized in the lactating mammary tissue to provide amino groups for the biosynthesis of other amino acids, such as glutamine and glutamate, which are necessary for neonatal growth and digestive tract maturation of the baby. They regulate mammary gland metabolism. There are multiple mechanisms for amino acids to enhance breast milk production. Protein synthesis and subsequent enhanced milk production in the mammary epithelial cells via activation of the mTOR cell signaling pathway is depicted in Figure 4.

Amino acids enhance milk production in the following ways:

1. Intravenous amino acid infusion
2. In plasma amino acid
3. In plasma osmolarity
4. Environmental stimuli: Light, Odor, Sound, Stress
5. Reproductive stimuli: mating, suckling

Fig. 4: Mechanism of action: amino acids in lactation

- Caseins are responsible for improving milk qualitatively and quantitatively. α-lactalbumins and β-lactoglobulins increase lactose content.
- Non-phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) inhibits protein synthesis by combining with the eukaryotic translation initiation factor 4E (eIF4E).
- Phosphorylation activates mTORC1 via 4EBP1 at multiple sites and subsequently causes the release of eIF4E from 4EBP1-eIF4E complex.
- Once released, eIF4E forms an active translation initiation complex. The translation initiation complex then binds the 40S ribosomal subunit, generating the 43S pre-initiation complex, thereby initiating translation of mRNA into protein.
- The mTORC1 receptor is activated by amino acids, particularly arginine, leucine, glycine, tryptophan, and glutamine.
- Leucine enhances overall protein synthesis by serving as a precursor for the synthesis of glutamine, aspartate, glutamate, and asparagine.
Constitutive proteins are actively synthesized by the cells of the mammary gland during lactation which accounts for 40–70% of total mammary protein synthesis. Mammals require large amounts of amino acids to support milk synthesis during lactation. The uptake of branched-chain amino acids by the mammary glands is much higher than their output in milk. Amino acids are catabolized extensively in lactating mammary tissue to provide amino groups for the biosynthesis of other amino acids, i.e., glutamine and glutamate which are necessary for neonatal digestive tract maturation and overall neonatal growth. The catabolism of amino acids by the mammary glandular epithelial cells is initiated by branched-chain amino acid transaminase in the presence of α-ketoglutarate to form branched-chain α-keto acids and glutamate. Thus, a concentration of branched-chain α-keto acids in milk is high and serves as energy substrates and differentiation of the small intestine of neonates. Substantial amounts of branched-chain α-keto acids are utilized by enterocytes of the small intestine and the splanchnic bed. They are responsible for the differentiation of the luminal epithelium of the mammary gland, thereby enhancing the milk-producing capacity of the same. Thus, amino acids are necessary for milk synthesis as well as for augmenting milk output. Figure 5 demonstrates the mechanism of i/v amino acid administration in enhancing breast milk production. Upon i/v administration, there is an increase in plasma amino acid concentration, which augments plasma osmolarity. Along with other stimulants, such as light, sound, estradiol, glucocorticoids, and progesterone, increased osmolarity activates the maternal hypothalamo-pituitary-adrenal (HPA) axis. The neuroendocrine neurons of the HPA axis release the prolactin regulatory factor which stimulates the neurointermediate lobe of the pituitary to release prolactin in the maternal circulation. In response to the suckling by the offspring, prolactin is responsible for the stimulation of milk synthesis in the mammary glands. Suckling by the baby activates ascending systems that decrease the release of dopamine, resulting in enhanced responsiveness to prolactin-releasing hormones, i.e., thyrotropin-releasing hormone. Premilk ejection, neurosecretory oxytocin population fires a synchronized burst of action potentials, resulting in the release of oxytocin from nerve terminals in the neurohypophysis. Oxytocin, synthesized in the magnocellular neurons of the supraoptic, hypothalamic, paraventricular, and accessory nuclei, is responsible for contracting the myoepithelial cells of the mammary gland to produce milk ejection. Neonatal growth, development, and health are sustained by human milk. Optimal health and growth of suckling neonates depends both quantitatively and qualitatively on milk production by their mothers. Milk synthesis of the lactating mammary gland is determined by the activity and the number of functional mammary epithelial cells, level of premature involution of the mammary gland, availability of precursors, stimulation of differentiation of various mammary epithelial cells, and concentration of lactogenic hormone. Lactogenic hormones, i.e., growth hormones, insulin, prolactin, and glucocorticoids are responsible for functional differentiation, proliferation, and involution of mammary epithelial cells. Translational and transcriptional regulation of gene expression of the mammary epithelial cells is modulated by lactogenic hormones. Amino acids regulate cell differentiation, cell cycle progression, cell apoptosis, and milk protein synthesis. Human mammary gland comprises epithelial cells, adipose tissue, and surrounding stroma. The epithelial cell in the lumen leads to synthesis and secretion of milk in the mammary gland. Milk upon synthesis is stored in the lactiferous tree duct. Upon suckling by the neonates, there is an oxytocin surge, which secretes milk. The synthesis of milk should be preceded by functional differentiation of the luminal epithelial cells. The quantity of functional mammary
epithelial cells is important for the gland’s milk synthetic capacity.21 Epithelial cells of the mammary gland undergo proliferation in both the pre- and post-partum periods for milk synthesis. Amino acids are the major components of milk proteins. They are nitrogenous precursors for the synthesis of glutamine, aspartate, alanine, and glutamate in the mammary gland.20 Amino acid transaminase–initiated pathways lead to abundant peptide bound and free glutamate, aspartate, asparagines, and glutamine in milk.20 Amino acids modulate cell metabolism via synthesis of macromolecules (DNA and proteins), thereby promoting cell growth in the mammary epithelial cells.21 Constitutive proteins account for 40–70% of total mammary protein synthesis in lactation.14 Synthesis of constitutive proteins in the mammary tissue is proportional to the number of functional mammillary epithelial cells. This physiological process is upregulated by amino acids.

Amino acids facilitate mammary gland maturation and differentiation by:

- Amino acids undergo protein synthesis by initiating mRNA translation by the mTOR pathway.23
- Amino acids stimulate phosphorylation of mTOR, thereby promoting translation initiation and polypeptide formation.20
- This results in growth, proliferation, and maturation of mammary epithelial cells.

This mechanism has important implications for the epigenetic regulation of lactogenesis. Amino acids, i.e., leucine and its metabolites, are secretagogues for insulin secretion by β-cells, partly through phosphorylation of mTOR downstream molecules p70S6K and 4EBP1, indicating the stimulatory role of amino acids in cell differentiation.20 In vitro and in vivo studies indicate that unlike the differentiating mammary epithelial cells, the undifferentiated and predifferentiated cells have low levels of mTOR phosphorylation.20 mTOR-mediated expression of the Id2 protein (inhibitor of DNA-binding protein) is a prerequisite for cell differentiation in the mammary gland.24 Functional differentiation of mammary secretory cells and development of the mammary gland is executed by activation of the mTOR pathway.25 It explains the stimulating effect of amino acids on protein synthesis and milk secretion by mammary epithelial cells. There is a seven-fold increase in the mitochondrial inner membrane density during lactation.26 Thereby, there is an increase in the activity and the number of mitochondria in the lactating mammary tissue. However, adenosine triphosphate production is required to support high rates of mitochondrial activity and the number of mitochondria in the lactating mammary tissue. Therefore, amino acids facilitate mammary gland maturation and differentiation by:

- Amino acids undergo protein synthesis by initiating mRNA translation by the mTOR pathway.23
- Amino acids stimulate phosphorylation of mTOR, thereby promoting translation initiation and polypeptide formation.20
- This results in growth, proliferation, and maturation of mammary epithelial cells.

In conclusion, amino acid supplementation is proven to be both efficacious and safe in augmenting breast milk production, thereby preventing lactation insufficiency. Healthy, full-term, exclusively breastfed infants lose weight in the first days following birth. I/v amino acid supplementation effectively prevents this physiological weight loss and promoted substantial weight gain over a period of 1 month after birth. Amino acids should be considered for preventing lactation insufficiency, thereby promoting growth, weight gain, and development of the neonate.

References


3. UNICEF Data: Infant and young child feeding; July 2018.


17. Wall E, McFadden T. Regulation of mammary development as it relates to changes in milk production efficiency. September 26, 2012.


